Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients

American Journal of Health-System Pharmacy

Volumn 68, Issue 23, 2011, Pages 2276-2282

  Marfo, Kwaku ^a   Akalin, Enver ^a   Wang, Cuiling ^b   Lu, Amy ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Antithymocyte globulin; Costs; Creatinine; Dosage; Dosage schedule; Graft rejection; Immunosuppressive agents; Pharmacoeconomics; Toxicity; Transplantation

Indexed keywords

ATOVAQUONE; CREATININE; DIPHENHYDRAMINE; GANCICLOVIR; HEPARIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PARACETAMOL; PREDNISONE; SULFAMETHOXAZOLE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM; VALGANCICLOVIR;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PHARMACOECONOMICS; PLASMAPHERESIS; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 82655181497     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110120     Document Type: Article

References (23)

1. Ciancio G, Burke GW, Miller J. Induction therapy in renal transplantation: an overview of current developments. Drugs. 2007; 67:2667-80. (Pubitemid 350224378)
2. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. Biodrugs. 2005; 19:39-46. (Pubitemid 40432506)
3. Genzyme Corporation. Thymoglobulin (rabbit anti-thymocyte globulin): U.S. prescribing information. www.thymoglobulin.com/home/thymo- pdf-pi.pdf (accessed 2010 Oct 20).
4. Pfizer Corporation. Atgam (equine anti-thymocyte globulin): U.S. prescribing information. www.pfizer.com/files/ products/uspi-atgam.pdf (accessed 2010 Sep 29).
5. Gaber AS, First R, Raymond J et al. Results of the double-blind, randomized, multicenter, phase II clinical trials of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66:29-37.
6. Buchler M, de Ligny BH, Madec C et al. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant. 2003; 17:539-45. (Pubitemid 37461433)
7. Mourad G, Garrigue V, Squifflet JP. Induction versus non-induction in renal transplant recipients with tacrolimusbased immunosuppression. Transplantation. 2001; 72:1050-5. (Pubitemid 32924076)
8. Thibaudin D, Alamartine E, de Filippis JP et al. Advantage of anti-thymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without anti-thymocyte globulin. Nephrol Dial Transplant. 1998; 13:711-5. (Pubitemid 28119056)
9. Brennan DC, Daller JA, Lake LD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355:1967-77. (Pubitemid 44708016)
10. Noel C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009; 20:1385-92.
11. Djamali A, Turc-Baron C, Portales P. Low dose anti-thymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000; 69:799-805. (Pubitemid 30174100)
12. Peddi VR, Bryant M, Roy-Chaudhury P et al. Safety, efficacy and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidneypancreas transplant recipients. Transplantation. 2002; 73:1514-8. (Pubitemid 34547476)
13. Abouna GM, al-Abdullah IH, Kelly-Sullivan D et al. Randomized clinical trial of anti-thymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation. 1995; 59:1564-8.
14. Uber WE, Uber LA, VanBakel AB. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc. 2004; 36:3245-9. (Pubitemid 41126785)
15. Wiland AM, Fink JC, Philosophe D et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc. 2001; 33:1910. (Pubitemid 32238116)
16. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713-23. (Pubitemid 29082898)
17. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006; 6:262-74. (Pubitemid 43382161)
18. Cosmi AB, Woris HH, Delmonico FL et al. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery. 1976; 80:155-63.
19. Grino JM, Alsina J, Sabater R. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Transplantation. 1990; 49:1114-7. (Pubitemid 20227637)
20. Thomas FT, Griesedieck C, Thomas J. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transplant Proc. 1984; 16:1561-3. (Pubitemid 15189239)
21. Clark KR, Forsythe JL, Shenton BK et al. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int. 1993; 6:18-21. (Pubitemid 23015177)
22. Mordacchini M, Calconi G, Di Falco G. CD3 and CD19 lymphocyte depletion following a course of anti-lymphocyte globulin in renal allograft recipients. Clin Transplant. 1992; 6:69.
23. Olausson M, Mjornstedt L, Brynger H et al. Steroid-resistant rejection in kidneytransplanted patients: is ATG treatment for three or ten days preferable? Transpl Int. 1996; 9(suppl 1):S38-40.